Use of natalizumab in persons with multiple sclerosis: 2022 update-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Use of natalizumab in persons with multiple sclerosis: 2022 update

Published:2022-09 Issue: Volume:65 Page:103995
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Morrow Sarah A.,Clift Fraser,Devonshire Virginia,Lapointe Emmanuelle,Schneider Raphael,Stefanelli Mark,Vosoughi Reza

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference81 articles.

1. TYSABRI (natalizumab) product monograph,2017

2. Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study;Barbin;Neurology,2016

3. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies;Baroncini;Mult. Scler.,2016

4. Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort;Bigaut;Mult. Scler.,2021

5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy;Bloomgren;N. Engl. J. Med.,2012

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of integrins in brain health and neurodegenerative diseases;European Journal of Cell Biology;2024-09

2. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment;Multiple Sclerosis and Related Disorders;2024-08

3. Multiple sclerosis treatment review for primary care providers;The Nurse Practitioner;2024-06-25

4. Deciphering Autoimmune Diseases: Unveiling the Diagnostic, Therapeutic, and Prognostic Potential of Immune Repertoire Sequencing;Inflammation;2024-06-25

5. Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review;Multiple Sclerosis and Related Disorders;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3